Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dmitri Mouradov

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Cancer Discovery|June 9, 2018
<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal TumorsAnuratha Sakthianandeswaren, Marie J Parsons, Dmitri Mouradov, et al.
Gut|January 8, 2021
Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriersPeter Georgeson, Bernard J Pope, Christophe Rosty, et al.
Oncotarget|May 12, 2016
Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancerNirosha Suraweera, Dmitri Mouradov, Shan Li, et al.
Cancer Research|November 10, 2012
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancerNicholas I Fleming, Robert N Jorissen, Dmitri Mouradov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2013
PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancerFiona L Day, Robert N Jorissen, Lara Lipton, et al.
Gastroenterology|June 20, 2017
Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug SensitivityJing Wang, Dmitri Mouradov, Xiaojing Wang, et al.
The Lancet. Gastroenterology & Hepatology|July 26, 2018
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based seriesEnric Domingo, Carme Camps, Pamela J Kaisaki, et al.
Communications Biology|June 5, 2025
Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell linesIan Y Luk, Jennifer K Mooi, Dmitri Mouradov, et al.
The Journal of Molecular Diagnostics : JMD|November 17, 2022
Evaluating Multiple Next-Generation Sequencing-Derived Tumor Features to Accurately Predict DNA Mismatch Repair StatusRomy Walker, Peter Georgeson, Khalid Mahmood, et al.
Cell Death and Differentiation|May 23, 2022
Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progressionIan Y Luk, Laura J Jenkins, Kael L Schoffer, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cancer Discovery|June 9, 2018
<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal TumorsAnuratha Sakthianandeswaren, Marie J Parsons, Dmitri Mouradov, et al.
Gut|January 8, 2021
Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriersPeter Georgeson, Bernard J Pope, Christophe Rosty, et al.
Oncotarget|May 12, 2016
Relative telomere lengths in tumor and normal mucosa are related to disease progression and chromosome instability profiles in colorectal cancerNirosha Suraweera, Dmitri Mouradov, Shan Li, et al.
Cancer Research|November 10, 2012
SMAD2, SMAD3 and SMAD4 mutations in colorectal cancerNicholas I Fleming, Robert N Jorissen, Dmitri Mouradov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2013
PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancerFiona L Day, Robert N Jorissen, Lara Lipton, et al.
Gastroenterology|June 20, 2017
Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug SensitivityJing Wang, Dmitri Mouradov, Xiaojing Wang, et al.
The Lancet. Gastroenterology & Hepatology|July 26, 2018
Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based seriesEnric Domingo, Carme Camps, Pamela J Kaisaki, et al.
Communications Biology|June 5, 2025
Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell linesIan Y Luk, Jennifer K Mooi, Dmitri Mouradov, et al.
The Journal of Molecular Diagnostics : JMD|November 17, 2022
Evaluating Multiple Next-Generation Sequencing-Derived Tumor Features to Accurately Predict DNA Mismatch Repair StatusRomy Walker, Peter Georgeson, Khalid Mahmood, et al.
Cell Death and Differentiation|May 23, 2022
Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progressionIan Y Luk, Laura J Jenkins, Kael L Schoffer, et al.
Pageof 5